{
  "nctrialId": "HC-1559",
  "title": "A Randomized Double-Blind, Placebo-Controlled  Study of BRE-701 (selective estrogen receptor modulator) in Patients With Cystic Fibrosis",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled  Study of BRE-701 (selective estrogen receptor modulator) in Patients With Cystic Fibrosis",
  "sponsor": "Centre for Addiction and Mental Health",
  "indication": "Cystic Fibrosis",
  "phase": "Phase 1/Phase 2",
  "fileName": "HC-1559.json",
  "fileSize": 135405,
  "date": "2024-08-31",
  "completionDate": "2026-04-18",
  "drugName": "BRE-701 (selective estrogen receptor modulator)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Withdrawn",
  "description": "This is a randomized double-blind, placebo-controlled  study designed to evaluate the efficacy and safety of BRE-701 (selective estrogen receptor modulator) in patients with Cystic Fibrosis. The study will enroll approximately 495 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 22-83 years\n- Confirmed diagnosis of Cystic Fibrosis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1559"
}